Amgen
One Amgen Center Drive
Thousand Oaks
CA
91320-1799
USA
805.447.1000
http://www.amgen.com
Product Categories
Pharmaceuticals

Related Content

Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL
News | ACC
American College of Cardiology Program to Increase Cholesterol Screenings

September 12, 2023 β€” The American College of Cardiology, through a strategic collaboration with Amgen and Esperion, is ...

Home September 12, 2023
arrow
NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases, today announced dose administration for the first patient in its PREVAIL study, a global Phase 3 cardiovascular outcomes trial of the novel cholesteryl ester transfer protein (CETP) inhibitor obicetrapib
News | Heart Failure
NewAmsterdam Pharma Doses First Patient in its PREVAIL Study
March 4, 2022 – NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of ...
Home March 04, 2022
arrow
The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients. #ACC21 #ACC2021 #GALACTICHF
News | Heart Failure
GALACTIC-HF Shows Omecamtiv Mecarbil Brings Greater Benefits for Severe Heart Failure

May 18, 2021 β€” The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a ...

Home May 18, 2021
arrow
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease

October 31, 2018 β€” Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects ...

Home October 31, 2018
arrow
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals
No Evidence of Cognitive Issues When Evolocumab Added to Statin Therapy

April 3, 2017 β€” There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes ...

Home April 03, 2017
arrow
Evolocumab, Repatha, LDL, ACC late breaker, best LDL lowering drug
Feature | Pharmaceuticals
Evolocumab Significantly Reduces Risk of Cardiovascular Events, LDL

March 20, 2017 β€” The most important late-breaking pharmaceutical trial at the 2017 America College of Cardiology annual ...

Home March 20, 2017
arrow
ivabradine (Corlanor)
Technology
FDA Approves Ivabradine to Treat Heart Failure

April 16, 2015 β€” The U.S. Food and Drug Administration (FDA) approved Amgen’s ivabradine (Corlanor) to reduce ...

Home April 16, 2015
arrow
Β© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now